How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Poliomyelitis Vaccine Market
- By Vaccine Type: Inactivated Poliovirus Vaccine (IPV), Oral Poliovirus Vaccine (OPV), Fractional Inactivated Poliovirus Vaccine (fIPV)
- By End User: Hospitals, Clinics, Immunization Centers, Public Health Programs, Pharmacies
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government Distribution Programs
- By Age Group: Infants (0-1 year), Children (1-12 years), Adolescents (13-18 years), Adults (19+ years)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Inactivated Poliovirus Vaccine (IPV) leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.163 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.171 →
Full report · locked preview
Everything inside the Poliomyelitis Vaccine Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 3
End User 5
Distribution Channel 4
Age Group 4
Companies profiled
Sanofi Pasteur
GlaxoSmithKline (GSK)
Bharat Biotech
Serum Institute of India
Bio Farma
Chiron Corporation (now part of Novartis)
Valneva SE
Sinovac Biotech
Panacea Biotec
Shantha Biotechnics (a Sanofi company)
Cadila Healthcare (Zydus Cadila)
Haffkine Bio-Pharmaceutical Corporation
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sanofi Pasteur
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bharat Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Serum Institute of India
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio Farma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Chiron Corporation (now part of Novartis)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Valneva SE
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sinovac Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Panacea Biotec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Shantha Biotechnics (a Sanofi company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cadila Healthcare (Zydus Cadila)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Haffkine Bio-Pharmaceutical Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Biological E. Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →LG Chem Life Sciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →
Global · 2025–2033
$4,600M by 2033 · 4.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Inactivated Poliovirus Vaccine (IPV)59.0
- Oral Poliovirus Vaccine (OPV)18.1
- Fractional Inactivated Poliovirus Vaccine (fIPV)23.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,070M → $1,427M · 3.7%
Europe$745.7M → $1,063M · 4.5%
Asia Pacific$680.9M → $950.1M · 4.3%
Latin America$421.5M → $603.8M · 4.6%
Middle East and Africa$324.2M → $432.4M · 3.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.422026
4.432027
4.442028
4.462029
4.472030
4.482031
4.492032
4.512033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sanofi Pasteur15.8
- GlaxoSmithKline (GSK)12.8
- Bharat Biotech6.5
- Serum Institute of India14.3
- Bio Farma5.7
- Chiron Corporation (now part of Novartis)17.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type20.2%
End User22.7%
Distribution Channel33.4%
Age Group23.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe23.8
- Asia Pacific21.2
- Latin America13.5
- Middle East and Africa9.7
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sanofi Pasteur | 96 | 86 | 75 | 81 | 91 | 85 | 86 |
| GlaxoSmithKline (GSK) | 90 | 85 | 83 | 76 | 76 | 92 | 84 |
| Bharat Biotech | 65 | 78 | 68 | 87 | 85 | 70 | 76 |
| Serum Institute of India | 62 | 70 | 70 | 70 | 80 | 58 | 68 |
| Bio Farma | 76 | 61 | 59 | 72 | 70 | 67 | 68 |
| Chiron Corporation (now part of Novartis) | 69 | 54 | 69 | 50 | 64 | 55 | 60 |
| Valneva SE | 51 | 50 | 60 | 55 | 49 | 48 | 52 |
| Sinovac Biotech | 52 | 43 | 59 | 43 | 45 | 42 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Bharat Biotech
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sanofi Pasteur | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| GlaxoSmithKline (GSK) | ✓ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Bharat Biotech | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| Serum Institute of India | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Bio Farma | ✓ | − | ◐ | ◐ | ◐ | ✓ |
| Chiron Corporation (now part of Novartis) | ◐ | − | ◐ | − | − | ◐ |
| Valneva SE | − | ◐ | ◐ | ◐ | − | − |
| Sinovac Biotech | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sanofi Pasteur86
2GlaxoSmithKline (GSK)84
3Bharat Biotech76
4Serum Institute of India68
5Bio Farma68
6Chiron Corporation (now part of Novartis)60
7Valneva SE52
8Sinovac Biotech47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Sanofi PasteurGlaxoSmithKline (GSK)
Challenger3
Strong scale, closing on the leaders.
Bharat BiotechSerum Institute of IndiaBio Farma
Contender1
Focused players with pockets of strength.
Chiron Corporation (now part of Novartis)
Niche2
Specialists in a single segment or region.
Valneva SESinovac Biotech
Go-to-market strategy
Land Vaccine Type in North America, then scale across Poliomyelitis Vaccine Market — a $410M beachhead inside a $6.51B market.
Beachhead (SOM)$410Mobtainable near-term
Serviceable (SAM)$2.32Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Inactivated Poliovirus Vaccine (IPV)
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer77 fit
Oral Poliovirus Vaccine (OPV)
Strong fit — clear ROI and a fast path to value.
End user66 fit
Fractional Inactivated Poliovirus Vaccine (fIPV)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Poliomyelitis Vaccine Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified25%
Evaluation13%
Closed-won7%
$15.3KCAC
$81KLTV
5.3:1LTV : CAC
< 5 moCAC payback
Investment thesis
Poliomyelitis Vaccine Market is a durable-growth opportunity — $866M by 2033, compounding at 9.5%.
TAM · 2025$420Mtoday
TAM · 2033$866Mforecast
CAGR9.5%2027–2033
Cumulative$5.57Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$866MTotal addressable market
SAM$357MServiceable available market
SOM$70MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.5% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$866MLarge & growingTAM by 2033 at 9.5% CAGR
$357MServiceable nowreachable with today’s model
$70MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$675MBear6.2% CAGR
$866MBase9.5% CAGR
$1.11BBull12.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Poliomyelitis Vaccine Market — a $12.3B market by 2033. Plan: grow share from 6.5% to 13.0%.
Market size · 2033$12.3Btotal addressable
Market CAGR10.8%2027–2033
Target share13.0%from 6.5% today
Revenue ambition$1.60Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.5% | 13.0% | Behind |
| Revenue | $811M | $1.60B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 37.4% | 45.0% | At risk |
| Customer retention | 88.8% | 95.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $235M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Sales deck · value proposition
Win the Poliomyelitis Vaccine Market conversation — a $1.97B market you can size, segment and defend in minutes.
Market size · 2033$1.97Btotal opportunity
Growth5.8%CAGR to 2033
Addressable buyers1,343+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 4 mopayback period
$55K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Sanofi PasteurGlaxoSmithKline (GSK)Bharat BiotechSerum Institute of IndiaBio FarmaChiron Corporation (now part of Novartis)Valneva SESinovac Biotech+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Poliomyelitis Vaccine Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Poliomyelitis Vaccine Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Seasonal Influenza Vaccines Market
Market size, share, segmentation and regional forecast.
$926M by 2031 · 7.06% CAGR
View reportOncology Drug Market
Market size, share, segmentation and regional forecast.
$13.2B by 2033 · 10.68% CAGR
View reportBiologic Therapeutics Drugs Market
Market size, share, segmentation and regional forecast.
$1.1B by 2033 · 4.44% CAGR
View reportSuperdisintegrants Market
Market size, share, segmentation and regional forecast.
$11.2B by 2033 · 6.23% CAGR
View reportBeta Blocker Market
Market size, share, segmentation and regional forecast.
$11.4B by 2033 · 4.09% CAGR
View reportHuman Vaccines Market
Market size, share, segmentation and regional forecast.
$4.5B by 2031 · 3.97% CAGR
View reportContraceptive Devices Market
Market size, share, segmentation and regional forecast.
$13.4B by 2033 · 3.39% CAGR
View reportNanoemulsions Market
Market size, share, segmentation and regional forecast.
$9.5B by 2033 · 9.37% CAGR
View reportOpioid Anesthetics Market
Market size, share, segmentation and regional forecast.
$12.0B by 2032 · 10.51% CAGR
View reportBiosimilar Monoclonal Antibodies Market
Market size, share, segmentation and regional forecast.
$4.9B by 2033 · 9.38% CAGR
View reportAnti-Retroviral Drugs Market
Market size, share, segmentation and regional forecast.
$8.1B by 2032 · 4.78% CAGR
View reportBone Morphogenetic Proteins Market
Market size, share, segmentation and regional forecast.
$12.5B by 2032 · 5.03% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.